# Stoke Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stoke-therapeutics

- Industry: Biotechnology
- Headquarters: Bedford, US
- Website: www.stoketherapeutics.com
- Total disclosed funding: $130M
- Latest round: Series B (Oct 22, 2018)
- Investors on record: 9

## About

Stoke Therapeutics, Inc. specializes in RNA-based therapies, focusing on enhancing gene expression to treat genetic disorders caused by haploinsufficiencies. Their innovative approach aims to transform treatment paradigms in severe diseases like Dravet syndrome.Founded in 2014 and headquartered in Bedford, US, Stoke Therapeutics develops RNA-based therapies targeting genetic diseases. The company, led by CEO Edward Kaye, has successfully pivoted towards innovative gene therapy solutions and raised USD 97.5 mn in their most recent funding round on November 19, 2020. This funding followed a previous IPO in June 2019, where they raised USD 142.04 mn. Stoke Therapeutics has engaged in a total of 4 deals since its inception.Stoke Therapeutics focuses on innovative RNA-based therapies, utilizing its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform. This platform is engineered to enhance protein production from genes that are partially dysfunctional, targeting genetic diseases like Dravet syndrome. Their flagship product, zorevunersen (STK-001), is under clinical evaluation with potential applications extending to conditions such as autosomal dominant optic atrophy (ADOA). The company primarily serves healthcare providers and families affected by genetic disorders in North America and Europe, seeking to deliver transformative therapeutic solutions.For the year 2024, Stoke Therapeutics reported revenue of USD 36.56 mn alongside an EBITDA of USD -99.20 mn. The company generates revenue through strategic partnerships and collaborations, sharing development costs and revenues from successful therapeutic products, including milestone payments and royalties from their leading product, zorevunersen (STK-001).Stoke Therapeutics aims to launch new products leveraging its TANGO platform, with ongoing clinical trials for zorevunersen (STK-001) poised to address Dravet syndrome and potentially other genetic disorders. The company plans to expand its market presence in North America and Europe, seeking to enhance partnerships and licensing agreements by 2024. Recent funding of USD 97.5 mn from November 2020 will be directed towards advancing their clinical trials and supporting the development of new therapeutic solutions.

## Funding rounds

- Series B, Oct 22, 2018, $90M — Alexandria Venture Investments, Apple Tree Partners, Redmile Group, RTW Investments, RA Capital Management, Cormorant Asset Management, Janus Henderson Investors, Perceptive Advisors, Sphera Funds Management
- Series A, Jan 4, 2018, $40M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Janus Henderson Investors — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Sphera Funds Management — Series B